Education
About Us
Working with TipRanks
Follow Us
Alpha Cognition Inc (ACOG)
NASDAQ:ACOG
ACOG Stock Chart & Stats
$5.70
<$0.01(0.02%)
At close: 4:00 PM EST
$5.70
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$3.75 - $11.54
Previous Close$5.43
Volume265.46K
Average Volume (3M)110.53K
Market Cap
$122.90M
Enterprise Value$110.01M
Total Cash (Recent Filing)$39.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 13, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding20,902,103
10 Day Avg. Volume118,269
30 Day Avg. Volume110,534
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue23.99
Enterprise Value/Gross Profit34.65
Enterprise Value/Ebitda-7.29
Forecast
1Y Price Target
$18.00Price Target Upside215.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash And Financial StabilityAlpha Cognition is expected to have sufficient cash to fund operations through to cash flow break-even.
Product Growth And Market PositionAlpha Cognition's lead product ZUNVEYL® is robustly positioned for long-term sales growth in the U.S. market.
Regulatory MilestonesChinese regulatory submission accepted for review by the National Medical Products Administration, potentially leading to approval next year.
Bears Say
Earnings And Sales ForecastThe full-year 2025 net sales forecast has been decreased to $5.7M from the prior $11.7M to reflect slower contracting and reimbursement.
Equity DilutionThe 12-month price target was reduced to $18 from $20 to account for the equity dilution from the most recent financing.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $3.75 and its highest was $11.54 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $122.90M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Nov 13, 2025 which is in 5 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Aug 14, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.19.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.43.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 20,902,103 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went down -19.92%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
Alpha Cognition Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (215.79% Upside)
$18.00 (215.79% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $122.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.71%
12-Months-Change
Fundamentals
Return on Equity
-131.23%
Trailing 12-Months
Asset Growth
2067.29%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased a successful launch of ZUNVEYL, strong revenue growth, and positive prescriber feedback, which were offset by increased operating and net losses, as well as challenges with prior authorizations. Overall, the highlights and positive indicators slightly outweigh the lowlights, suggesting a cautiously optimistic outlook.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$18.00
▲(215.79% Upside)
Technical Analysis
Sangamo Biosciences
―
Elicio Therapeutics
―
Cognition Therapeutics
―
Lucid Diagnostics
―
Nuvectis Pharma
―
Ownership Overview
Options Prices
Currently, No data available
---